Acadia Pharmaceuticals Enhances Parkinson's Campaign with Ryan Reynolds
Decision brief
Answer first · skim in under a minute
Acadia Pharmaceuticals has launched an enhanced campaign for Parkinson's disease featuring Ryan Reynolds. This article explores the implications for the pharmaceutical sector.
Acadia Pharmaceuticals expanded its Parkinson's disease education push by pairing with Ryan Reynolds on More to Parkinson's, an unbranded campaign that puts hallucinations and delusions of Parkinson's disease psychosis in front of caregivers and clinicians.
Contents9 sections
Key Takeaways
- On August 14, 2024, Acadia and Ryan Reynolds announced the multi-channel More to Parkinson's disease-education campaign.
- The campaign highlights Parkinson's-related hallucinations and delusions and features personal caregiver stories from Reynolds and his mother, Tammy.
- Acadia markets NUPLAZID (pimavanserin), FDA-approved in April 2016 for hallucinations and delusions associated with Parkinson's disease psychosis.
- In 2026 Business Wire updates, Acadia said it renewed the Reynolds partnership and reported awareness of hallucinations and delusions rising from 8% to over 30% in the Parkinson's community since launch.
What happened with Acadia's Parkinson's campaign?
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) launched More to Parkinson's as an educational campaign to raise awareness among caregivers, patients, and care providers about Parkinson's-related hallucinations and delusions.
The August 14, 2024 announcement, issued via Business Wire and carried on Acadia's media site, cast Ryan Reynolds — described as a Parkinson's disease advocate whose father lived with the disease — as a central storyteller alongside his mother, Tammy.
Acadia framed the effort as unbranded disease education distributed across digital, social, and connected-TV channels, with discussion guides and videos on risk, symptom recognition, and how to talk with a doctor.
How does the campaign connect to Nuplazid?
More to Parkinson's is unbranded, but Acadia's commercial portfolio includes FDA-regulated NUPLAZID (pimavanserin).
In a January 2026 Business Wire J.P. Morgan update, Acadia reiterated that pimavanserin was approved by FDA in April 2016 under the trade name NUPLAZID for hallucinations and delusions associated with Parkinson's disease psychosis.
That same update said Acadia renewed the Ryan Reynolds partnership for More to Parkinson's, citing strong resonance with patients and caregivers and plans for new creative.
Marketing compliance teams should keep the unbranded awareness layer separate from branded NUPLAZID promotion in media plans and call notes.
What awareness gap is Acadia trying to close?
Parkinson's disease education historically emphasizes tremor and motor disability. Non-motor neuropsychiatric symptoms often arrive later in clinician conversations.
Acadia executives have publicly argued that a large share of patients may experience hallucinations or delusions while far fewer raise the issue with clinicians. The campaign's job is to normalize that discussion.
In the January 2026 investor update, Acadia said awareness of hallucinations and delusions among the Parkinson's disease community rose from 8% to over 30% since the campaign launched. Those figures are company-reported survey metrics, not an independent epidemiology study.
What should competing Parkinson's marketers watch?
Celebrity disease-education partnerships can move search and social volume quickly, but they also invite scrutiny on authenticity, disclosure, and off-label risk.
Competitors in movement-disorder and neuropsychiatry markets should track three signals: whether More to Parkinson's creative stays unbranded, whether Acadia pairs it with branded NUPLAZID digital funnels, and whether peer companies respond with caregiver-led storytelling of their own.
Acadia's later 2025–2026 Business Wire congress releases keep reminding investors that NUPLAZID remains the only FDA-approved treatment specifically for Parkinson's disease psychosis, reinforcing why awareness spend and branded detailing travel together.
What to watch next
Watch Acadia's disclosure of campaign KPIs beyond awareness: physician conversation rates, referral pull-through, and NUPLAZID new-patient starts.
Also watch pipeline catalysts Acadia has flagged around Alzheimer's disease psychosis and Lewy body dementia psychosis programs, which could reuse similar non-motor-symptom education playbooks.
For patient-safety context on Parkinson's disease broadly, CDC and NIH educational pages remain useful public baselines, while product claims must stay anchored to FDA labeling for pimavanserin.
Compliance reviewers should confirm that celebrity scripts disclose sponsorship, avoid disease-cure language, and do not imply that every person with Parkinson's disease psychosis is a candidate for NUPLAZID without a clinician assessment.
Commercial teams can pair the education wave with earlier specialist reach, but they still need clean adverse-event reporting pathways if patient inquiries rise after high-reach media flights.
Related NovaPharma coverage
- Biogen-Eisai Leqembi access coverage
- Related FDA approval coverage
- Specialty launch and access analysis
Frequently Asked Questions
What is Acadia's More to Parkinson's campaign?
More to Parkinson's is an Acadia-sponsored unbranded disease-education campaign, announced with Ryan Reynolds on August 14, 2024, to raise awareness of Parkinson's-related hallucinations and delusions.
What FDA-approved therapy does Acadia market for Parkinson's disease psychosis?
Acadia markets NUPLAZID (pimavanserin), which FDA approved in April 2016 for hallucinations and delusions associated with Parkinson's disease psychosis.
Why does Acadia emphasize non-motor Parkinson's symptoms?
Company executives say hallucinations and delusions are common yet under-discussed, and that awareness gaps delay clinician conversations about Parkinson's disease psychosis management.
Primary Sources
Acadia Pharmaceuticals pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
